1. Home
  2. FSEA vs ENTX Comparison

FSEA vs ENTX Comparison

Compare FSEA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Seacoast Bancorp Inc.

FSEA

First Seacoast Bancorp Inc.

HOLD

Current Price

$16.83

Market Cap

52.7M

Sector

Finance

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.18

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSEA
ENTX
Founded
1890
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.7M
58.2M
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
FSEA
ENTX
Price
$16.83
$1.18
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
23.9K
62.0K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$16.57
Revenue Growth
N/A
N/A
52 Week Low
$10.13
$0.91
52 Week High
$16.90
$3.22

Technical Indicators

Market Signals
Indicator
FSEA
ENTX
Relative Strength Index (RSI) 77.51 49.18
Support Level $16.60 $1.17
Resistance Level N/A $1.37
Average True Range (ATR) 0.05 0.06
MACD -0.15 -0.01
Stochastic Oscillator 44.83 27.27

Price Performance

Historical Comparison
FSEA
ENTX

About FSEA First Seacoast Bancorp Inc.

First Seacoast Bancorp Inc is the savings and loan holding company. The banks business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one- to four-family residential real estate loans, commercial real estate and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. It operates in single segment of Banking Services.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: